Patient characteristics
| Characteristic . | N = 581 n (%) . |
|---|---|
| Age at thrombosis (y), mean ± SD | 64.2 ± 11.4 |
| Sex | |
| Female | 211 (36.4) |
| Male | 368 (63.6) |
| Comorbidities | |
| Cirrhosis | 257 (44.2) |
| Previous major hemorrhage | 67 (11.5) |
| Abdominal surgery in past 3 mo | 35 (6.0) |
| Previous VTE | 30 (5.2) |
| Cancer diagnosis∗ | |
| Hepatobiliary | 321 (55.2) |
| Pancreatic | 128 (22.0) |
| Colorectal | 31 (5.3) |
| Lymphoma | 23 (4.0) |
| Stomach | 17 (2.9) |
| Breast | 15 (2.6) |
| Leukemia | 13 (2.2) |
| Kidney | 11 (1.9) |
| Prostate | 8 (1.4) |
| Esophageal | 5 (0.9) |
| Lung | 5 (0.9) |
| Small intestine | 5 (0.9) |
| Endometrial | 4 (0.7) |
| Melanoma | 4 (0.7) |
| Ovarian | 4 (0.7) |
| Sarcoma | 4 (0.7) |
| Bladder | 3 (0.5) |
| Head and neck | 3 (0.5) |
| Myeloma | 2 (0.3) |
| Nonmelanoma skin | 1 (0.2) |
| Thyroid | 1 (0.2) |
| Other | 23 (4.0) |
| Cancer stage (n = 560) | |
| Local | 133 (23.8) |
| Locally advanced | 199 (35.5) |
| Metastatic | 228 (40.7) |
| Cancer status | |
| Active (diagnosed or treated within last 6 mo) | 525 (92.8) |
| In remission | 41 (7.2) |
| Medications at time of SpVT | |
| Antiplatelet | 113 (19.4) |
| Anticoagulant | 32 (5.5) |
| Systemic cancer therapy | 116 (20.0) |
| Thrombosis location∗ | |
| Portal vein | 519 (89.3) |
| Hepatic vein | 35 (6.0) |
| Splenic vein | 66 (11.4) |
| Superior mesenteric vein | 119 (20.5) |
| Inferior mesenteric vein | 6 (1.0) |
| Extent of SpVT (n = 387) | |
| Completely occlusive | 123 (31.8) |
| Partially occlusive | 264 (68.2) |
| Type of SpVT | |
| Bland | 408 (70.6) |
| Tumor | 115 (19.9) |
| Mixed | 32 (5.5) |
| Uncertain | 23 (4.0) |
| Presenting signs or symptoms of SpVT∗ | |
| Abdominal pain | 246 (42.3) |
| Nausea or vomiting | 49 (8.4) |
| Ascites | 57 (9.8) |
| Jaundice | 46 (7.9) |
| Abnormal liver function tests | 66 (11.4) |
| GI bleed | 27 (4.6) |
| Ischemic bowel | 4 (0.7) |
| Incidental finding | 190 (32.7) |
| Other | 147 (25.3) |
| Concurrently diagnosed usual-site VTE | |
| DVT | 15 (2.6) |
| PE | 14 (2.4) |
| Baseline laboratory results, mean ± SD | |
| Hemoglobin (g/dL) | 10.8 ± 2.1 |
| Platelets (K/μL) | 194 ± 137 |
| Creatinine (mg/dL) | 1.1 ± 0.8 |
| Prothrombin time (s) | 18.3 ± 13.2 |
| Partial thromboplastin time (s) | 47.7 ± 32.3 |
| Treatment within 2 wk of diagnosis | |
| Therapeutic anticoagulation | 228 (39.2) |
| Unfractionated heparin | 33 (14.5) |
| Warfarin | 42 (18.4) |
| LMWH | 98 (43.0) |
| DOAC | 55 (24.1) |
| Fondaparinux | 0 (0.0) |
| Mechanical thrombectomy | 23 (4.0) |
| Baseline platelet count | |
| ≥100 × 103/μL | 310 (60.6) |
| 75 × 103/μL - 99 × 103/μL | 65 (12.7) |
| 50 × 103/μL - 74 × 103/μL | 72 (14.1) |
| <50 × 103/μL | 65 (12.7) |
| Characteristic . | N = 581 n (%) . |
|---|---|
| Age at thrombosis (y), mean ± SD | 64.2 ± 11.4 |
| Sex | |
| Female | 211 (36.4) |
| Male | 368 (63.6) |
| Comorbidities | |
| Cirrhosis | 257 (44.2) |
| Previous major hemorrhage | 67 (11.5) |
| Abdominal surgery in past 3 mo | 35 (6.0) |
| Previous VTE | 30 (5.2) |
| Cancer diagnosis∗ | |
| Hepatobiliary | 321 (55.2) |
| Pancreatic | 128 (22.0) |
| Colorectal | 31 (5.3) |
| Lymphoma | 23 (4.0) |
| Stomach | 17 (2.9) |
| Breast | 15 (2.6) |
| Leukemia | 13 (2.2) |
| Kidney | 11 (1.9) |
| Prostate | 8 (1.4) |
| Esophageal | 5 (0.9) |
| Lung | 5 (0.9) |
| Small intestine | 5 (0.9) |
| Endometrial | 4 (0.7) |
| Melanoma | 4 (0.7) |
| Ovarian | 4 (0.7) |
| Sarcoma | 4 (0.7) |
| Bladder | 3 (0.5) |
| Head and neck | 3 (0.5) |
| Myeloma | 2 (0.3) |
| Nonmelanoma skin | 1 (0.2) |
| Thyroid | 1 (0.2) |
| Other | 23 (4.0) |
| Cancer stage (n = 560) | |
| Local | 133 (23.8) |
| Locally advanced | 199 (35.5) |
| Metastatic | 228 (40.7) |
| Cancer status | |
| Active (diagnosed or treated within last 6 mo) | 525 (92.8) |
| In remission | 41 (7.2) |
| Medications at time of SpVT | |
| Antiplatelet | 113 (19.4) |
| Anticoagulant | 32 (5.5) |
| Systemic cancer therapy | 116 (20.0) |
| Thrombosis location∗ | |
| Portal vein | 519 (89.3) |
| Hepatic vein | 35 (6.0) |
| Splenic vein | 66 (11.4) |
| Superior mesenteric vein | 119 (20.5) |
| Inferior mesenteric vein | 6 (1.0) |
| Extent of SpVT (n = 387) | |
| Completely occlusive | 123 (31.8) |
| Partially occlusive | 264 (68.2) |
| Type of SpVT | |
| Bland | 408 (70.6) |
| Tumor | 115 (19.9) |
| Mixed | 32 (5.5) |
| Uncertain | 23 (4.0) |
| Presenting signs or symptoms of SpVT∗ | |
| Abdominal pain | 246 (42.3) |
| Nausea or vomiting | 49 (8.4) |
| Ascites | 57 (9.8) |
| Jaundice | 46 (7.9) |
| Abnormal liver function tests | 66 (11.4) |
| GI bleed | 27 (4.6) |
| Ischemic bowel | 4 (0.7) |
| Incidental finding | 190 (32.7) |
| Other | 147 (25.3) |
| Concurrently diagnosed usual-site VTE | |
| DVT | 15 (2.6) |
| PE | 14 (2.4) |
| Baseline laboratory results, mean ± SD | |
| Hemoglobin (g/dL) | 10.8 ± 2.1 |
| Platelets (K/μL) | 194 ± 137 |
| Creatinine (mg/dL) | 1.1 ± 0.8 |
| Prothrombin time (s) | 18.3 ± 13.2 |
| Partial thromboplastin time (s) | 47.7 ± 32.3 |
| Treatment within 2 wk of diagnosis | |
| Therapeutic anticoagulation | 228 (39.2) |
| Unfractionated heparin | 33 (14.5) |
| Warfarin | 42 (18.4) |
| LMWH | 98 (43.0) |
| DOAC | 55 (24.1) |
| Fondaparinux | 0 (0.0) |
| Mechanical thrombectomy | 23 (4.0) |
| Baseline platelet count | |
| ≥100 × 103/μL | 310 (60.6) |
| 75 × 103/μL - 99 × 103/μL | 65 (12.7) |
| 50 × 103/μL - 74 × 103/μL | 72 (14.1) |
| <50 × 103/μL | 65 (12.7) |
DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; LMWH, low molecular weight heparin; PE, pulmonary embolism; SD, standard deviation.
Patients can have multiple attributes, and thus totals may sum to more than 100%.